Alphatec Holdings, Inc., a medical technology company, designs, develops and advances technologies for the surgical treatment of spinal disorders. The company is headquartered in Carlsbad, California.
| Revenue (TTM) | $839.72M |
| Gross Profit (TTM) | $598.31M |
| EBITDA | $52.92M |
| Operating Margin | 1.74% |
| Return on Equity | -308.10% |
| Return on Assets | -2.02% |
| Revenue/Share (TTM) | $5.42 |
| Book Value | $-0.01 |
| Price-to-Book | 85.66 |
| Price-to-Sales (TTM) | 1.36 |
| EV/Revenue | 2.125 |
| EV/EBITDA | 43.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 12.60% |
| Shares Outstanding | $153.33M |
| Float | $122.65M |
| % Insiders | 20.54% |
| % Institutions | 75.68% |
Volatility is currently expanding
Alphatec Holdings missed Wall Street's third-quarter 2026 consensus on both adjusted EPS and revenue, and ATEC shares fell sharply as the market reacted. Levi & Korsinsky is investigating potential securities law violations on behalf of investors who lost money.
Alphatec Holdings is rated Hold with a $7.80 target, reflecting strong surgical volume growth but declining revenue per procedure and persistent cash flow challenges. Q3 saw 20% more surgeries and 25% more new surgeons, but a 5% drop in revenue per surgery due to weaker biologics sales, impacting overall revenue quality. Gross margin improved to 71.5%, yet margin gains were partly driven by a lower biologics mix, while negative free cash flow and rising debt remain key concerns.
In recent years, Alphatec Holdings has consistently outperformed sales expectations and gained share in the $8 billion U.S. spinal disorder treatment market. However, FY2026 is not playing out as initially expected by management. Last week, Alphatec reported disappointing Q3 results and reduced full-year expectations for revenue, Adjusted EBITDA and free cash flow. Management attributed the shortfall to a combination of execution issues and weakening market trends.
ATEC shares sold off after Alphatec Holdings named a temporary international supply constraint among the reasons for its lower 2026 revenue outlook. Levi & Korsinsky is investigating whether the Company's earlier disclosures about its international business met its obligations under the federal securities laws ATEC shares sold off after Alphatec Holdings named a temporary international supply constraint among the reasons for its lower 2026 revenue outlook. Levi & Korsinsky is investigating whether the Company's earlier disclosures about its international business met its obligations under the federal securities laws
LOS ANGELES--(BUSINESS WIRE)---- $ATEC--ATEC Investors Have Opportunity to Join Alphatec Holdings, Inc. Fraud Investigation with SBS Law.
Alphatec Holdings maintained approximately $882 million in 2026 revenue guidance on August 4, then cut the outlook to approximately $862 million with its third-quarter results. Levi & Korsinsky is investigating on behalf of ATEC shareholders who lost money.
ATEC's stock recently dropped more than 35%; Ademi LLP is investigating Alphatec for potential securities fraud. CLICK HERE TO JOIN MILWAUKEE, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating possible securities fraud claims against Alphatec (Nasdaq: ATEC).
Alphatec slashes its full-year outlook as fewer surgeons have purchased its add-on bone-graft products used for spinal fusion.
Alphatec Holdings, Inc. (ATEC) Q3 2026 Earnings Call Transcript
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced that Thomas "Tommy" Carls has joined the company as Executive Vice President, Data Intelligence and Strategy. Carls will report directly to Chairman and Chief Executive Officer, Pat Miles, and will serve as a member of ATEC's Senior Leadership Team. In this newly created role, Carls will lead ATEC'.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ATEC and any ticker you trade — then tracks every position and per-strategy win rate.
